| Title |
METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay |
| ID_Doc |
10980 |
| Authors |
Pong, YH; Su, YR; Lo, HW; Ho, CK; Hsieh, CC; Chu, CT; Chen-Yang, YW; Tsai, VFS; Wu, JC; Wu, GJ |
| Title |
METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay |
| Year |
2020 |
| Published |
Cancer Biomarkers, 27, 3 |
| DOI |
10.3233/CBM-191001 |
| Abstract |
BACKGROUND: METCAM/MUC18 expression was increased with the malignant progression of prostate cancer and also a bona fide metastatic gene, capable of initiating and driving the metastasis of a non-metastatic human prostate cancer cell line to multiple organs. OBJECTIVE: We explored if METCAM/MUC18 was detectable in human serum and a novel biomarker to predict malignant propensity of prostate cancer. MATERIALS AND METHODS: Two antibodies were identified by Western blot analysis having the highest sensitivity and specificity to establish calibration curves from the recombinant METCAM/MUC18 proteins. They were used in ELISA and LFIA to determine the METCAM/MUC18 concentrations in serum samples from 8 normal individuals, 4 BPH patients, 1 with PIN, 6 with high-grade prostate cancer, and 2 treated cancer patients. RESULTS: Serum METCAM/MUC18 concentrations were statistically significantly higher in the patients with PIN and prostate cancer than those with BPH, the treated patients and normal individuals. The LFIA results were statistically better than ELISA and Western blot methods. Serum METCAM/MUC18 concentrations were in direct proportional to most of serum PSA concentrations. CONCLUSIONS: METCAM/MUC18 antigen was detectable in human serum samples. METCAM/MUC18 may serve as an early diagnostic biomarker for malignant potential of prostate cancer and at least complement the PSA test. |
| Author Keywords |
METCAM/MUC18; Western blot; ELISA; gold nanoparticles; LFIA; malignant potential; prostate cancer |
| Index Keywords |
Index Keywords |
| Document Type |
Other |
| Open Access |
Open Access |
| Source |
Science Citation Index Expanded (SCI-EXPANDED) |
| EID |
WOS:000519697500010 |
| WoS Category |
Oncology |
| Research Area |
Oncology |
| PDF |
|